艾迪联合吉西他滨与顺铂化疗方案治疗晚期非小细胞肺癌的回顾性研究  

Retrospective analysis of gemcitabine plus cisplatin chemotherapy regimen combined with Aidi injection in the treatment of patients with advanced non-small cell lung cancer

作　　者：孙蕾[1] 顾亮[2] 

机构地区：[1]丽水市中心医院呼吸科,浙江丽水32300 [2]浙江医院呼吸内科,杭州310013

出　　处：《中国临床药理学杂志》2014年第5期405-407,共3页The Chinese Journal of Clinical Pharmacology

基　　金：浙江省中医药科学研究基金资助项目(2013ZB016)

摘　　要：目的评价艾迪联合吉西他滨与顺铂化疗方案（GP）治疗晚期非小细胞肺癌（NSCLC）的临床疗效和安全性。方法收治晚期NSCLC患者69例，单用GP化疗为对照组（36例）：吉西他滨1000mg·m-2，iv，d1，8；顺铂30mg·m-2，iV，d2-4；GP联合艾迪化疗方案作为试验组（33例），在GP方案基础上，加艾迪50mL，iv，qd，10d，均化疗4个周期，评价2组患者化疗临床疗效及不良反应。结果试验组客观有效率（30．3％）明显高于对照组（12．1％）（P〈0．05）；试验组胃肠道反应及血液学毒性等化疗相关不良反应明显低于对照组（P〈0．05）。结论艾迪联合GP化疗方案治疗晚期NSCLC可以显著提高临床疗效，降低不良反应。Objective To evaluate the clinical efficacy and safety of gemcitabine plus eisplatin （GP） chemotherapy regimen combined with Aidi injection in the treatment of advanced non - small cell lung cancer （NSCLC）. Methods Sixty -nine NSCLC patients treated with GP chemotherapy regimen were included in this study. Of the included 69 subjects, 36 treated with GP regiments only （gemcitabine 1000 -2 -2 mg-m ,iv, day 1,8;cisplatin 30 mg· m-2 , iv, day 2 -4） were deemed as the control group and 33 subjects treated with GP regimen combined with Aidi injection （50 mL ＋ 5% glucose 250 mL, iv, qd, 10 days） were considered as the treatment group. The clinical efficacies and adverse drug reaction of the two groups were compared after four - cycle chemotherapy repectively. Results The objective response rate （ORR） of the treatment group （30.3%）was higher than that of the control group （ 12. 1% ） （ P 〈 0. 05 ）. The gastrointestinal reactions and hematologic toxicity in treatment group were much lower than those in control group （P 〈 0. 05 ）. Conclusion The GP chemotherapy regimen combined with Aidi injection can improve clinical efficacy and decreased adverse drug reaction in the treatment of advanced non - small cell lung cancer.

关 键 词：艾迪注射液 晚期非小细胞肺癌 化疗 吉西他滨 顺铂 

分 类 号：R730.53[医药卫生—肿瘤] R979.1[医药卫生—临床医学]